Zydus Lifesciences Ltd. NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

968.90 1.25 (0.13%)

26.84% Fall from 52W High

1.1M

NSE+BSE Volume

NSE 16 Jul, 2025 3:31 PM (IST)

US FDA Approval

Zydus Lifesciences receives US FDA approval for Celecoxib Capsules, with a market size of $122.6 mn See details

Zydus Lifesciences Ltd. share price target

Zydus Lifesciences Ltd. has an average share price target of 988.60. The consensus estimate represents an upside of 2.03% from the last price of 968.90. View 9 reports from 5 analysts offering long-term price targets for Zydus Lifesciences Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	16 Jul 2025	Zydus Lifesciences	Consensus Share Price Target	968.90	967.20	-	-0.18	hold	pdf Detailed Estimates
	02 Jan 2023	Zydus Lifesciences	Ashika Research	968.90	480.00	420.10 (130.64%)	Target met	Buy	pdf post cache		Broker Report Ashika - Stock Picks Zydus Lifesciences Ltd. - January 2023 Ashika Research pdf Copy Link Share on Share on Share on Share on Alert
	14 Nov 2022	Zydus Lifesciences	ICICI Direct Target	968.90	480.00	423.80 (128.62%)	Target met	Hold	pdf post cache		Broker Report Zydus Life Sciences ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	14 Nov 2022	Zydus Lifesciences	Prabhudas Lilladhar Reco Target	968.90	465.00	416.75 (132.49%)	Target met	Accumulate	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	14 Nov 2022	Zydus Lifesciences	ICICI Securities Limited Target	968.90	448.00	423.80 (128.62%)	Target met	Hold	pdf post cache		Broker Report Moraiya cleared; Revlimid launched ICICI Securities Limited Zydus Lifesciences (Zydus) reported Q2FY23 performance is broadly in line with our estimates. Revenue grew 7.3% YoY to Rs40.0bn (I-Sec: Rs40.0bn) on the back of India and US markets. pdf Copy Link Share on Share on Share on Share on Alert
	12 Nov 2022	Zydus Lifesciences	Motilal Oswal Reco Target	968.90	410.00	423.80 (128.62%)	Target met	Neutral	pdf post cache		Broker Report India and US drives while Consumer Wellness and API drag earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2022	Zydus Lifesciences	ICICI Direct	968.90	405.00	386.85 (150.46%)	Target met	Hold	pdf post cache		Broker Report Zydus Life Sciences ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 Aug 2022	Zydus Lifesciences	Prabhudas Lilladhar Target	968.90	425.00	386.85 (150.46%)	Target met	Buy	pdf post cache		Broker Report ZYDUS LIFESCIENCES L Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	11 Aug 2022	Zydus Lifesciences	ICICI Securities Limited Target	968.90	411.00	364.55 (165.78%)	Target met	Accumulate	pdf post cache		Broker Report Operationally weak performance ICICI Securities Limited Zydus Lifesciences (Zydus) reported tepid operational performance in Q1FY23. pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Zydus Lifesciences	Geojit BNP Paribas Target	968.90	440.00	363.20 (166.77%)	Target met	Buy	pdf post cache		Broker Report ZYDUS LIFESCIENCES LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2022	Zydus Lifesciences	Prabhudas Lilladhar Target	968.90	450.00	373.40 (159.48%)	Target met	Buy	pdf post cache		Broker Report ZYDUS WELLNESS LTD. Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners